Ruth Helen Palmer

This study identifies cholinergic neurons as the key circuit for Neurofibromin-regulated sleep consolidation in Drosophila NF1 models, revealing Ras/MAPK signaling dysregulation and mutation-specific mechanisms.

This study identifies RUVBL1 and RUVBL2 as druggable regulators of MYCN in neuroblastoma, showing their inhibition reduces MYC signaling and induces cell cycle arrest and apoptosis.

This study shows ALK R1275Q mutation sustains an immature SCP-like cell state during sympathoadrenal commitment, increasing susceptibility to MYCN-driven neuroblastoma initiation.

The paper uses spatial transcriptomics to analyze neuroblastoma microenvironments, identifying novel paracrine interactions between cancer cells and surrounding cells.

This study shows that combining ATR and ALK inhibitors improves survival in MYCN-amplified neuroblastoma mouse models lacking ALK mutations.

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

The paper identifies Sparkly, a novel neuropeptide precursor gene regulated by Alk signaling in Drosophila CNS, through integration of TaDa and scRNA-seq data.

The paper identifies Kahuli as an Alk target in Drosophila visceral mesoderm using DamID profiling and shows its role in midgut constriction.

The paper demonstrates that ALKALs activate ALK/LTK family receptors and are involved in neural crest development using zebrafish and Drosophila models.

This study characterizes Drosophila Ndg mutants, showing loss of Ndg impairs basement membrane stability, permeability, and nervous system function.

This study identifies Cnk and Ave as downstream effectors of Alk signaling in Drosophila visceral founder cell specification, showing their necessity for proper development.